Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium

Mvila, Gertrude Luyeye; Batalansi, Donatien Babaka; Praet, Marleen; Marchal, Guy; Laenen, Annouschka; Christiaens, Marie-Rose; Brouckaert, Olivier; Ali-Risasi, Catherine; Neven, Patrick; Ongeval, Chantal Van

doi:10.1016/j.breast.2015.07.031

Cited by 17 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…compared a BC series diagnosed in Kinshasa (Africans) with a European series of BC diagnosed in Leuven and found that the first group presented BC at younger ages and mainly ER-negative and HER2-positive tumours, when compared to the Caucasian group. However, no difference in the rate of triple-negative BC was observed [ 36 ]. Ly M et al .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Breast cancer in Angola, molecular subtypes: a first glance

Miguel¹,

Lopes²,

Ferreira³

et al. 2017

ecancer

View full text Add to dashboard Cite

PurposeThe aim of this study was to investigate the breast cancer (BC) molecular subtypes according to its surrogate immunohistochemistry (IHC) markers. We conducted a preliminary study, to correlate the clinical pathological profiles and molecular subtypes of breast cancer in Luanda, Angola.MethodsFrom January 2011 to 30 December 2014, 140 consecutive cases of microscopically confirmed invasive breast carcinoma were classified regarding histology and IHC (ER, PR, HER2, and Ki-67). Surrogate molecular subtypes were classified according to ESMO recommendations.ResultsAll patients were female; the median age was 47 years (24–84 years). Invasive carcinoma NST was the most common type (91.4%) and grade 2 was prevalent (70.7%). Most tumours were locally advanced (stage III – 65% and stage IV – 3.6%). In 140 studied cases, 74 (52.8%) malignancies were hormone receptor positive; 25.7% were luminal A like, 19.3% luminal B and HER2 negative like, 7.9% luminal B and HER2-positive like, 15.7% HER2 positive, and 31.4% were triple negative.ConclusionWomen’s BC in Luanda-Angola is diagnosed at a young age and at an advanced stage. The two predominant molecular subtypes are HR positive and triple negative. The percentage of HER2-positive BC cases was high. Determining the molecular subtype using surrogate IHC markers has important treatment and prognostic implications for Angolan women with BC. There is an urgent need to study a prospective BC series in order to confirm the present results.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Our results and abovementioned studies regarding ER negative were aggregated in Figure 1 . In Table 2 , we compare our results with the available SSA breast cancer phenotype data [ 32 – 34 , 36 , 38 , 44 – 46 ]. We found that results from Luanda, Angola are quite similar to those described in neighbouring countries.…”

Section: Discussionmentioning

confidence: 99%

Breast cancer in Angola, molecular subtypes: a first glance

Miguel¹,

Lopes²,

Ferreira³

et al. 2017

ecancer

View full text Add to dashboard Cite

show abstract

“…Over expression of HER 2 is reported in 18% of Malian patients, 26% in South Africa, 22% in Uganda, 17.5% in Sudan, and 27% in Egypt showing differences within the continent [ 29 – 33 ]. Luyeye et al compared to breast cancer molecular subtypes between Congo and Belgium and found higher Her2 over expression rates in older Congolese women compared to Belgians [ 34 ].…”

Section: Epidemiologymentioning

confidence: 99%

An update on the management of breast cancer in Africa

Vanderpuye

Grover

Hammad

et al. 2017

Infect Agents Cancer

135

124

View full text Add to dashboard Cite

BackgroundThere is limited information about the challenges of cancer management and attempts at improving outcomes in Africa. Even though South and North Africa are better resourceds to tackle the burden of breast cancer, similar poor prognostic factors are common to all countries. The five-year overall Survival rate for breast cancer patients does not exceed 60% for any low and middle-income country (LMIC) in Africa. In spite of the gains achieved over the past decade, certain characteristics remain the same such as limited availability of breast conservation therapies, inadequate access to drugs, few oncology specialists and adherence to harmful socio-cultural practices. This review on managing breast cancer in Africa is authored by African oncologists who practice or collaborate in Africa and with hands-on experience with the realities.MethodsA search was performed via electronic databases from 1999 to 2016. (PubMed/Medline, African Journals Online) for all literature in English or translated into English, covering the terms “breast cancer in Africa and developing countries”. One hundred ninety were deemed appropriate.ResultsBreast tumors are diagnosed at earlier ages and later stages than in highincome countries. There is a higher prevalence of triple-negative cancers. The limitations of poor nursing care and surgery, inadequate access to radiotherapy, poor availability of basic and modern systemic therapies translate into lower survival rate. Positive strides in breast cancer management in Africa include increased adaptation of treatment guidelines, improved pathology services including immuno-histochemistry, expansion and upgrading of radiotherapy equipment across the continent in addition to more research opportunities.ConclusionThis review is an update of the management of breast cancer in Africa, taking a look at the epidemiology, pathology, management resources, outcomes, research and limitations in Africa from the perspective of oncologists with local experience.

show abstract

“…Most studies aim to reveal insight into tumour biology in Africa. There are reports from Ghana [ 28 , 29 ], the Republic of Congo [ 30 ], Kenya [ 31 ], Tanzania [ 32 , 33 ] and Ethiopia [ 34 ]. Some efforts were also made to publish results from established IHC services locally, with experiences reported from the Ivory Coast [ 35 ], Nigeria [ 36 ], Uganda [ 25 ], Angola [ 37 ], Ethiopia [ 38 ] and others.…”

Section: Discussionmentioning

confidence: 99%

Breast cancer pathology services in sub-Saharan Africa: a survey within population-based cancer registries

Ziegenhorn

Frie

Ekanem

et al. 2020

BMC Health Serv Res

View full text Add to dashboard Cite

Background Pathologists face major challenges in breast cancer diagnostics in sub-Saharan Africa (SSA). The major problems identified as impairing the quality of pathology reports are shortcomings of equipment, organization and insufficiently qualified personnel. In addition, in the context of breast cancer, immunohistochemistry (IHC) needs to be available for the evaluation of biomarkers. In the study presented, we aim to describe the current state of breast cancer pathology in order to highlight the unmet needs. Methods We obtained information on breast cancer pathology services within population-based cancer registries in SSA. A survey of 20 participating pathology centres was carried out. These centres represent large, rather well-equipped pathologies. The data obtained were related to the known population and breast cancer incidence of the registry areas. Results The responding pathologists served populations of between 30,000 and 1.8 million and the centres surveyed dealt with 10–386 breast cancer cases per year. Time to fixation and formalin fixation time varied from overnight to more than 72 h. Only five centres processed core needle biopsies as a daily routine. Technical problems were common, with 14 centres reporting temporary power outages and 18 centres claiming to own faulty equipment with no access to technical support. Only half of the centres carried out IHC in their own laboratory. For three centres, IHC was only accessible outside of the country and one centre could not obtain any IHC results. A tumour board was established in 13 centres. Conclusions We conclude that breast cancer pathology services ensuring state-of-the-art therapy are only available in a small fraction of centres in SSA. To overcome these limitations, many of the centres require larger numbers of experienced pathologists and technical staff. Furthermore, equipment maintenance, standardization of processing guidelines and establishment of an IHC service are needed to comply with international standards of breast cancer pathology.

show abstract

Prognostic features of breast cancer differ between women in the Democratic Republic of Congo and Belgium

Cited by 17 publications

References 20 publications

Breast cancer in Angola, molecular subtypes: a first glance

Breast cancer in Angola, molecular subtypes: a first glance

An update on the management of breast cancer in Africa

Breast cancer pathology services in sub-Saharan Africa: a survey within population-based cancer registries

Contact Info

Product

Resources

About